Detail akcie Hutchison Rg online

Business Summary: HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, HUTCHMED (China) Ltd revenues decreased 25% to $630.2M. Net income decreased 63% to $37.7M. Revenues reflect Immunology- R&D segment decrease of 75% to $91.8M, Other venture segment decrease of 14% to $266.8M. Net income also reflects Foreign Exchange Gains decrease of 42% to $5.1M (income), Interest expense increase from $759K to $2.9M (expense).